Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

被引：8
|
作者：
Yu, E. [1 ]
Piulats, J. M. [2 ]
Gravis, G. [3 ]
Fong, P. C. C. [4 ]
Todenhoefer, T. [5 ]
Laguerre, B. [6 ]
Arranz Arija, J. A. [7 ]
Oudard, S. [8 ]
Massard, C. [9 ,10 ]
Stoeckle, M. [11 ]
Nordquist, L. T. [12 ]
Carles, J. [13 ]
Kolinsky, M. P. [14 ]
Augustin, M. [15 ]
Gurney, H. [16 ,17 ]
Tafreshi, A. [18 ]
Li, X. T. [19 ]
Poehlein, C. H. [19 ]
Schloss, C. [19 ]
de Bono, J. S. [20 ]
机构：
[1] Univ Washington, Med Oncol, Seattle, WA 98195 USA
[2] Catalan Inst Oncol, Med Oncol, Barcelona, Spain
[3] Inst Paoli Calmettes, Med Oncol, Paris, France
[4] Auckland City Hosp, Med Oncol, Auckland, New Zealand
[5] Studienpraxis Urol, Urol, Nuertingen, Germany
[6] Ctr Eugene Marquis, Med Oncol, Rennes, France
[7] Gen Univ Hosp Gregorio Maranon, Med Oncol, Madrid, Spain
[8] Hop Europeen Georges Pompidou, Med Oncol, Paris, France
[9] Gustave Roussy Canc Campus, Med Oncol, Villejuif, France
[10] Paris Sud Univ, Villejuif, France
[11] Saarland Univ Hosp, Urol, Homburg, Germany
[12] Urol Canc Ctr, GU Res Network, Med Oncol, Omaha, NE USA
[13] Vall dHebron Univ Hosp, Genitourinary Oncol, Barcelona, Spain
[14] Cross Canc Inst, Med Oncol, Edmonton, AB, Canada
[15] Paracelsus Med Univ, Urol, Nurnberg, Germany
[16] Westmead Hosp, Med Oncol, Sydney, NSW, Australia
[17] Macquarie Univ Hosp, Sydney, NSW, Australia
[18] Univ Wollongong, Med Oncol, Wollongong, NSW, Australia
[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[20] Royal Marsden NHS Fdn Trust, Med Oncol, London, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
612P
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [21] KEYNOTE-365 COHORT D: PEMBROLIZUMAB PLUS ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Piulats, Josep
    Ferrario, Cristiano
    Linch, Mark
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose
    Todenhoefer, Tilman
    Fong, Peter
    Berry, William
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard
    Joshua, Anthony
    Conter, Henry
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A378 - A378
  • [22] Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
    Conter, Henry Jacob
    Shore, Neal D.
    Berry, William R.
    Fong, Peter C. C.
    Rodriguez, Jose Maria M. Piulats
    Appleman, Leonard Joseph
    Todenhoefer, Tilman
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    De Bono, Johann S.
    Kam, Audrey E.
    Emmenegger, Urban
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] PEMBROLIZUMAB PLUS ENZALUTAMIDE IN ABIRATERONE-PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: UPDATED RESULTS FROM KEYNOTE-365 COHORT C
    Yu, Evan Y.
    Fong, Peter
    Piulats, Josep M.
    Appleman, Leonard
    Conter, Henry
    Feyerabend, Susan
    Shore, Neal
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    de Bono, Johann S.
    Kam, Audrey
    Emmenegger, Urban
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian
    Berry, William
    JOURNAL OF UROLOGY, 2020, 203 : E368 - E368
  • [24] KEYNOTE-365 Cohort B: Pembrolizumab Plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer-New Data After an Additional 1 Year of Follow-Up
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 8 - 9
  • [25] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Kolinsky, Michael Paul
    Gravis, Gwenaelle
    Mourey, Loic
    Piulats, Josep M.
    Sridhar, Srikala S.
    Romano, Emanuela
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Appleman, Leonard Joseph
    Boegemann, Martin
    De Bono, Johann S.
    Joshua, Anthony M.
    Emmenegger, Urban
    Conter, Henry Jacob
    Laguerre, Brigitte
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
    Joshua, A. M.
    Gurney, H.
    Retz, M.
    Tafreshi, A.
    Fong, P. C. C.
    Shore, N. D.
    Romano, E.
    Augustin, M.
    Piulats, J. M.
    Berry, W. R.
    Kolinsky, M. P.
    Sridhar, S. S.
    Conter, H. J.
    Todenhoefer, T.
    Appleman, L. J.
    Wu, H.
    Schloss, C.
    Poehlein, C. H.
    de Bono, J. S.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1325 - S1325
  • [27] Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) one to three from KEYNOTE-199.
    Goh, Jeffrey C.
    Piulats Rodriguez, Jose Maria M.
    Gross-Goupil, Marine
    Vaishampayan, Ulka N.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Haiyan
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Wu, Haiyan
    Schloss, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.
    Ferrario, Cristiano
    Piulats, Josep M.
    Linch, Mark David
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose A.
    Todenhofer, Tilman
    Fong, Peter C. C.
    Berry, William R.
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard Joseph
    Joshua, Anthony M.
    Conter, Henry Jacob
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    YuJewish, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [30] Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study
    Antonarakis, E. S.
    Piulats, J. M.
    Gross-Goupil, M.
    Goh, J. C.
    Vaishampayan, U. N.
    De Wit, R.
    Alanko, T. V.
    Fukasawa, S.
    Tabata, K.
    Feyerabend, S.
    Berger, R.
    Ojamaa, K.
    Hoimes, C. J.
    Sezer, A.
    Omlin, A. G.
    Yachnin, J.
    Niu, C.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2021, 32 : S651 - S652
12345